Pyxis Oncology, Inc. (PYXS)
| Market Cap | 216.49M -23.9% |
| Revenue (ttm) | 11.04M +291.4% |
| Net Income | -86.71M |
| EPS | -1.27 |
| Shares Out | 119.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,054,515 |
| Open | 1.700 |
| Previous Close | 1.680 |
| Day's Range | 1.700 - 1.990 |
| 52-Week Range | 1.030 - 5.550 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 8.22 (+354.25%) |
| Earnings Date | Nov 5, 2026 |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o... [Read more]
Financial Performance
In 2025, Pyxis Oncology's revenue was $13.86 million, a decrease of -14.17% compared to the previous year's $16.15 million. Losses were -$79.62 million, 2.96% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price target is $8.22, which is an increase of 354.25% from the latest price.
News
Pyxis Oncology announces updated results from ongoing Phase 1 MICVO study
Pyxis Oncology (PYXS) earlier announced updated results from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin, or MICVO, in patients with second-line and beyond recurrent/...
William Blair upgrades Pyxis on head and neck cancer data
William Blair upgraded Pyxis Oncology (PYXS) to Outperform from Market Perform without a price target following the Phase 1 data evaluating micvotabart pelidotin in patients with second-line and beyon...
Pyxis Oncology upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Pyxis Oncology (PYXS) to Outperform from Market Perform.
Pyxis Oncology Transcript: Study update
In 33 efficacy-evaluable patients, MICVO showed a 39% confirmed ORR, 6.7-month median PFS and 81% 12-month OS probability; median OS was not reached. The dose cap reduced adverse events while maintaining efficacy, and a global phase III trial is planned for mid-2027.
Pyxis Oncology Press release: Study update
Pyxis Oncology issued a press release on November 19, 2026, disclosing material business information to investors.
Pyxis Oncology Slides: Study update
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on November 19, 2026.
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months
Pyxis Oncology Transcript: Stifel 2026 Healthcare Conference 2026
MICVO’s September second-line data showed a 36% response rate, 94% disease control rate and 6.2-month median PFS. Management plans a 500-patient pivotal trial starting in mid-2027, pending dose alignment and an H1 2027 OS update.
Pyxis Oncology Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
September phase I data showed a 36% response rate and encouraging survival signals in heavily pretreated head and neck cancer, with manageable safety after dose-cap changes. Headliner is being prepared as a pivotal second-line trial, alongside frontline combination updates planned for December and H2 2027.
Pyxis Oncology price target lowered to $7 from $8 at Wedbush
Wedbush lowered the firm’s price target on Pyxis Oncology (PYXS) to $7 from $8 and keeps an Outperform rating on the shares after the company reported third quarter financials and…
Pyxis Oncology price target lowered to $5 from $7 at Stifel
Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $5 from $7 and keeps a Buy rating on the shares.
Pyxis Oncology reports Q3 EPS (28c), consensus (24c)
“The September monotherapy data reinforce our confidence in MICVO’s potential to serve a significant population of patients with previously treated recurrent/metastatic head and neck cancer,” said Tom...
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) showed compelling efficacy data with a manageable safety profil...
Pyxis Oncology Quarterly report: Q3 2026
Pyxis Oncology has published its Q3 2026 quarterly earnings report on November 5, 2026.
Pyxis Oncology Earnings release: Q3 2026
Pyxis Oncology released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Pyxis Oncology Slides: Corporate presentation
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom...
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-b...
Pyxis Oncology Proxy statement: Proxy filing
Pyxis Oncology filed a proxy statement on October 21, 2026, providing details for shareholder voting and corporate governance matters.
Pyxis Oncology Proxy statement: Proxy filing
Pyxis Oncology filed a proxy statement on October 9, 2026, providing details for shareholder voting and corporate governance matters.
Pyxis Oncology announces closing of up to $282.6M public offering
Pyxis Oncology (PYXS) announced that it closed its previously announced registered public offering on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, be...
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today a...
Pyxis Oncology 36M share Spot Secondary priced at $2.90
Leerink, Guggenheim and Wells Fargo acted as joint book running managers for the offering.
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pri...
Pyxis Oncology announces common stock offering, no amount given
Pyxis Oncology (PYXS) announced that it has commenced a registered public offering of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants…